BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.

Abstract

Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.

• Authors: J Jawień, M Gajda, R Olszanecki, R Korbut
• Journal: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society (J Physiol Pharmacol) Vol. 58 Issue 3 Pg. 583-8 (Sep 2007) ISSN: 0867-5910 [Print] Poland
• PMID: 17928652 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Apolipoproteins E
• Azo Compounds
• Lipoxygenase Inhibitors
• Quinolines
• Receptors, LDL
• 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid
• oil red O

Topics

• Animals
• Aorta (drug effects, metabolism, pathology)
• Apolipoproteins E (genetics, metabolism)
• Atherosclerosis (drug therapy, genetics, metabolism)
• Azo Compounds (chemistry)
• Female
• Lipoxygenase Inhibitors (chemistry, pharmacology, therapeutic use)
• Mice
• Mice, Inbred C57BL
• Mice, Knockout
• Molecular Structure
• Quinolines (chemistry, pharmacology, therapeutic use)
• Receptors, LDL (genetics, metabolism)
• Staining and Labeling (methods)